NEW YORK, April 16, 2019 (GLOBE NEWSWIRE) — The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. 

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO)
Class Period: August 4, 2016 to January 31, 2019
Lead Plaintiff Deadline: April 26, 2019

The lawsuit alleges that AVEO Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the TIVO‑3 trial was inadequately designed to address the OS concerns regarding AVEO’s lead candidate drug, tivozanib, from the TIVO-1 trial presented in June 2013; (ii) tivozanib had insufficient survival data to meet FDA approval following its initial 2013 rejection; (iii) this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and (iv) as a result, AVEO’s public statements were materially false and misleading at all relevant times.

Get additional information about the AVEO lawsuit: http://www.kleinstocklaw.com/pslra-1/aveo-pharmaceuticals-inc-loss-submission-form?wire=3

Diplomat Pharmacy, Inc. (NYSE: DPLO)
Class Period: February 26, 2018 to February 21, 2019
Lead Plaintiff Deadline: April 25, 2019

The lawsuit alleges that throughout the class period, Diplomat Pharmacy, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Diplomat had downplayed its success in integrating and growing its PBM business, which included LDI Integrated and National Pharmaceutical, two companies Diplomat had acquired in late 2017; (2) consequently, Diplomat would need to record a non-cash impairment charge upwards of approximately $630 million relating to its PBM business and these 2017 acquisitions; (3) due to the foregoing, Diplomat would withdraw its preliminary 2019 full-year outlook issued less than seven weeks prior; and (4) as a result, defendants’ statements about Diplomat’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Get additional information about the DPLO lawsuit: http://www.kleinstocklaw.com/pslra-1/diplomat-pharmacy-inc-loss-submission-form?wire=3

United Microelectronics Corporation (NYSE: UMC)
Class Period: October 28, 2015 to November 1, 2018
Lead Plaintiff Deadline: May 13, 2019

The complaint alleges that throughout the class period United Microelectronics Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) UMC conspired with Fujian to steal trade secrets from Micron relating to its research and development of Dynamic Random-Access Memory (“DRAM”); (ii) UMC hired former Micron employees for the purpose of stealing such information from Micron; (iii) the foregoing conduct placed UMC and certain of its employees at an increased risk of criminal and regulatory investigation by the U.S. government; and (iv) as a result, UMC’s public statements were materially false and misleading at all relevant times.

Get additional information about the UMC lawsuit: http://www.kleinstocklaw.com/pslra-1/united-microelectronics-corporation-loss-submission-form?wire=3

NIO Inc. (NYSE: NIO)
Class Period: Purchasers of American Depositary Shares between September 12, 2018 and March 5, 2019
Lead Plaintiff Deadline: May 13, 2019

The lawsuit alleges that NIO Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) NIO would not be building its own manufacturing plant and would instead continue to rely on JAC Auto to manufacture its vehicles; (2) reductions in government subsidies for electric cars would materially impact NIO’s sales; and (3) as a result, Defendants’ statements about NIO’s business, operations, and prospects were materially false and misleading at all  relevant times.

Get additional information about the NIO lawsuit: http://www.kleinstocklaw.com/pslra-1/nio-inc-loss-submission-form?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com